Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Study connect Webseite durchsuchen
  • NCT03771859

Active, Not Recruiting

A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed - CA209-8RX

Aktualisiert: 7 September, 2021   |   ClinicalTrials.gov

Zusammenfassung zum Ausdrucken

SIND SIE AN DIESER STUDIE INTERESSIERT?
Drucken Sie diese Seite und den Leitfaden zu klinischen Studien aus, damit Sie sie mit Ihrem Arzt besprechen können.
Nutzen Sie unseren Leitfaden zu klinischen Studien, um mehr über die Schritte für die Teilnahme zu erfahren. Informieren Sie sich über die wichtigsten Punkte, über die Sie nachdenken sollten, und die Fragen, die Sie dem Studienteam stellen sollten, bevor Sie sich für eine Teilnahme entscheiden.
Diese Seite drucken CA209-8RX
Leitfaden herunterladen

SPRACHE AUSWÄHLEN

Studiendetails

  • Geschlecht(er)

  • 18+

    Altersgruppe

  • Active, Not Recruiting

Behandlungsmöglichkeiten

Studienarme
ZUGEWIESENE BEHANDLUNG
Participants who initiate adjuvant treatment with nivolumab

Wichtigste Eignungskriterien

Inclusion Criteria: - Patients with a primary diagnosis of melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection and have no evidence of disease. - Decision to treat with adjuvant nivolumab therapy has already been taken - At least 18 years of age at the time of treatment decision - Patients who provide written informed consent to participate in the study Exclusion Criteria: - Any patient with a current diagnosis of persisting advanced melanoma - Any patient currently enrolled in an interventional clinical trial for his/her melanoma treatment (note: patients who have completed their participation in an interventional trial or who are no longer receiving the study drug and are only followed up for OS/RFS can be enrolled. In case of a blinded study, the treatment arm needs to be known). Other protocol defined inclusion/exclusion criteria could apply

Wir empfehlen Ihnen dringend, sich an Bristol Myers Squibb zu wenden, um Nebenwirkungen (unerwünschte Ereignisse) zu melden.
Nebenwirkungen (unerwünschte Ereignisse) und andere meldepflichtige Ereignisse werden hier definiert
Nebenwirkungen (unerwünschte Ereignisse) oder Produktqualitätsbeschwerden melden: Medizinische Information